SBWire

Retinal Vein Occlusion - Pipeline Review, H1 2014

CEL-SCI Corporation, a late-stage oncology company, today announced that the Company is a Gold Sponsor of the Congress on Head and Neck Oncology (ECHNO 2014), which will be held in Liverpool, England from April 24th through 26th, 2014. CEL-SCI will sponsor a symposium regarding its investigational immunotherapy candidate Multikine®* (Leukocyte Interleukin, Injection) and its ongoing Phase III head and neck cancer trial with Multikine. Company representatives will be available at conference booth #10.

Aeolus Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014

Cardioxyl Pharmaceuticals, Inc. - Product Pipeline Review - 2014

AlbireoPharma - Product Pipeline Review - 2014

Silence Therapeutics plc - Product Pipeline Review - 2014

Cough - Pipeline Review, H1 2014

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

ImmunGene, Inc. - Product Pipeline Review - 2014

BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2014

Viron Therapeutics, Inc. - Product Pipeline Review - 2014

Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014

Bharat Biotech International Limited - Product Pipeline Review - 2014

Chimerix, Inc. - Product Pipeline Review - 2014

Perennial Allergic Rhinitis - Pipeline Review, H1 2014

Pertussis - Pipeline Review, H1 2014

Biodel Inc. - Product Pipeline Review - 2014

Orexo AB - Product Pipeline Review - 2014

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Global Markets Direct's, 'Down Syndrome - Pipeline Review, H1 2014', provides an overview of the Down Syndrome's therapeutic pipeline.

Food Allergy - Pipeline Review, H1 2014

Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.

Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014', provides an overview of the Amyotrophic Lateral Sclerosis's therapeutic pipeline.

GlobalData's clinical trial report, "Malignant Ascites Global Clinical Trials Review, H1, 2014" provides data on the Malignant Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.